Beneficial Effects of Non-Depleting Anti-CD4 in MRL/Mp-lpr/lprMice with Active Systemic Lupus Erythematosus and Microscopic Angiitis

References

• Harper JM., Thiru S. Lockwood CM, Cooke A. Myeloperox-idase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-/pr//pnnice: a spontaneous model for human microscopic angiitis. Eur J Immunol 1998. 28: 2217–26.
   Google Scholar
• Jabs DA, Burek CL, Hu Q, Kuppers RC, Lee B, Pendergast RA. Anti-CD4 antibody therapy suppresses autoimmune dis-ease in MRLIMp-lprilpr mice. Cell Immunol 1992. 141: 496-507.
   Google Scholar
• Gilkeson GS, Spumey R, Coffman TM., Kurlander R, Ruiz P, Pisrtsky DS. Effect of anti-CD4 antibody treatment on inflammatory arthritis in MRL-Ipr/lpr mice. Clin Immunol Immunopathol 1992. 64: 166–72.
   Google Scholar
• 0 Sullivan FX, Ray CJ, Takeda Y, Gordon, CS, Walker SE. Long-term anti-CD4 treatment of MRLI1pr mice ameliorates immunopathology and lymphoproliferation but fails to sup-press rheumatoid factor production. Clin Immunol Immun-opathol 1991. 61: 421-35.
   Google Scholar
• Jabs DA, Kuppers RC, Saboori AM., Burek CL, Enger C, Lee B et al. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRLIMp-lpr/lpr mice. Cell Immunol 1994. 154: 66–77.
   Google Scholar
• Davidson WF, Calkins C, Hugin A, Giese T, Holmes KL. Cytokine secretion by C3H-/pr and gld T cells: hypersecre-don of IFN-y and TNF-a by stimulated CDeT cells. J Immunol 1991. 146: 4138–48.
   Google Scholar
• Giese T and Davidson WF. Evidence for early onset, polyclo-nal activation of T cell subsets in mice homozygous for Apr. J Immunol 1992. 149: 3097–106.
   Google Scholar
• Pisetsky DS, Caster SA, Roths JB, Murphey ED. Apr gene control of the anti-DNA antibody response. J Immunol 1982. 128: 2322–25.
   Google Scholar
• Brostoff SW and Mason DW. Experimental allergic encepha-lomyelitis: successful treatment in vivo with a monoclonal antibody that rcognizes T helper cells. J Immunol 1984. 133: 1938–42.
   Google Scholar
• Flynn JC, Conway DH, Cobbald S, Waldmann H, Kong YC. Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal anti-bodies alters the development of adoptively transferred experimental autoimmune thyroiditis. Cell Immunol 1989. 122: 377–90.
   Google Scholar
• Ranges GE, Sriram S. Cooper SM. Prevention of type II col-lagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985. 162: 1105–10.
   Google Scholar
• Koike T, Itoh Y, Ishi L, Takabayashi K, Maruyama N, Tomi-oka H et al. Preventitive effect of monoclonal anti-L3T4 anti-body on development of diabetes in NOD mice. Diabetes 1987. 36: 539–41.
   Google Scholar
• Benjamin RJ. and Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986.320: 449–51.
   Google Scholar
• Waldor MK, Sriram S, Hardy R, Herzenberg LA, Herzenberg LA, Lanier L et al. Reversal of experimental allergic enceph-alomyelitis with a monoclonal antibody to a T cell marker. Science 1985. 227: 415–17.
   Google Scholar
• Hom JT, Butler LD, Riedl PE, Bendele AM. The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharma-cological agents which inhibit T cell activities. Eur J Immu-nol 1988. 18: 881-88.
   Google Scholar
• Issacs JD, Burrows N, Wing M., Keogan MT, Rebell° PRUB, Watts RA et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997. 110: 158–66.
   Google Scholar
• Lockwood CM., Thint S, Lomas DA, Stewart S, Drummond C, Elliott J et al. Refractory Wegener’s granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J Royal Coil Phys Lond 1998. 32: 473–78.
   Google Scholar
• Choy EHS, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheum 1998, 37: 484–90.
   Google Scholar
• Choy EH, Pitzalis C, Cauli A, Biji JA, Schantz A, Woody Jet al. Percentage of anti-CD4 monoclonal antibody-coated lym-phocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immuno-therapeutic dosing regimens. Arthritis & Rheum 1996. 39: 52–56.
   Google Scholar
• Rep MHG, van Oosten BW, Roos MTh, Ad& Hi, Polman CH, van Lier RAW. Treatment with depleting CD4 mono-clonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-y secreting TH1 cells. J Clin Invest 1997. 99: 2225–31.
   Google Scholar
• Brett Si, Rowan W, Smith M, Bartholomew M, Tite JP. Dif-ferential functional effects of a humanized anti-CD4 anti-body on resting and activated human T cells. Immunology 1997. 91: 346–53.
   Google Scholar
• Maini R, William St Clair E, Breedveld F, Furst D, Kalden J, Weisman M et al. Inflixmab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a ran-domised phase III trial. Lancet 1999. 354: 1932–39.
   Google Scholar
• Taylor PC, Peters AM, Paleolog E, Chapman FT, Elliott MJ, McCloskey R et al. Reduction of chemoldne levels and leu-kocyte traffic to joints by tumour necrosis a blockade in patients with rheumatoid arthritis. Arthritis & Rheum 2000. 43: 38–47.
   Google Scholar
• Mauri C, Chu CQ, Woodrow D, Mori L, Londei M. Treat-ment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J Immunol 1997. 159: 5032–41.
   Google Scholar
• Panayi GS, Choy EHS, Connolly DJA, Regan T, Manna VK, Rapson N et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 mono-clonal antibody (mAb) treatment I: suppression of disease activity and acute phase response. Arthritis Rheum 1996. 39 (suppl.): S244.
   Google Scholar
• Falk R, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. 1990. 87: 4115-19.
   Google Scholar
• Radic MZ, Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994. 12: 487–520.
   Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WI) et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992. 116: 488-98.
   Google Scholar
• Talar Williams C, Hijazi YM, Walther MM, Lineham WM, Hallan CW, Lubensky I et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener’s granu-lomatosis. Ann Intern Med 1996. 124: 477–84.
   Google Scholar